最初礼来成功研发GLP-1的艾塞那肽，作为FIC为糖尿病患者提供了新的选择，但半衰期短，一周需要两次注射给药，给患者依从性带来不小挑战；接着诺和诺德的利拉鲁肽和礼来的度拉糖肽接连上市，分别把给药频率降低到了一天一次和一周一次；直到2017年，诺和诺德推出了鼎鼎大名的司美格鲁肽，一周一次注射给药，同时另辟蹊径推出了口服版本，双方的竞争在不断迭代中，持续升温。

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

在为期 193 周的研究中，替尔泊肽的总体安全性和耐受性特征与之前发表的 SURMOUNT-1 72 周结果一致。最常报告的是胃肠道相关不良事件，如腹泻 ...

When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year. That won't ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...

具体而言，BGM0504针对减重适应证的2期临床试验（登记号：CTR20233198）是一项随机、双盲、安慰剂平行对照研究，共纳入120例中国非糖尿病超重或肥胖受试者。

说到减肥药，司美格鲁肽和替尔泊肽可谓是两座高山。全球大佬带货，民间供不应求，诺和诺德和礼来赚的盆满钵满。2023年上半年，司美格鲁肽减重版Wegovy销售额为30.75亿美元，替尔泊肽减重版Zepound销售额为17.61亿美元，两者合计48.36亿 ...

The authors examined the percent change in body weight from randomization to week 72 (SURMOUNT-1, -2, and -3) or week 52 (SURMOUNT-4), as well as the proportions of participants achieving the ...

PANO - Under the direction of the Quang Binh provincial Border Guard Command, agencies and units sent troops and vehicles to ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...